Online first
Review paper
Published online: 2024-09-27
Tracing prostate cancer — the evolution of PET-CT applications
Abstract
Background: The study aimed to overview radiopharmaceuticals used for the nuclear medicine (NM) imaging of prostate cancer (Pca) since the first mentions in the literature up to recent reports, with the special focus on positron emission tomography-computed tomography (PET-CT) radiotracers.
Materials and methods: We found over 3500 articles discussing the role of PET-CT in Pca patients’ management published within 1990–2023. We summarized the past and present interests of the Authors when the Pca diagnostic imaging and the use of radiotracers in Pca diagnosis are considered. Eventually, we have compared the radiotracers’ introduction in the
literature with the United States (U.S.) Food and Drug Administration (FDA) approval timeline.
Results: The most mentions by the Authors were made of the following PET-CT study compounds: 2-[18F]fluoroethyl-choline ([18F]FECh), gallium-68-labelled prostate-specific membrane antigen using peptide-11, ([68Ga]Ga-PSMA-11), carbon-11-labelled acetic acid ([11C]acetate), and the anti-1-amino-3–[18F]-fluorocyclobutane-1-carboxylic acid (anti-3-[18F]FACBC, Axumin®), as well as the non-tumour-specific 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG). The most recent studies analysis showed an increasing interest of the Authors not only in a relatively new Pca-specific [68Ga]Ga-PSMA-11, but also in a widely used non-specific [18F]FDG.
Conclusions: The literature analysis results lead to the conclusion that Pca remains a constant focus of the NM drug development with particularly high interest in PET-CT-dedicated radiotracers.
Keywords: oncologyprostate cancerprostatic neoplasmsPSMAradiopharmaceuticalpositron emission tomography
References
- Pianou NK, Stavrou PZ, Vlontzou E, et al. More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT. Hell J Nucl Med. 2019; 22(1): 6–9.
- Gupta M, Choudhury PS, Rawal S, et al. Risk stratification and staging in prostate cancer with prostatic specific membrane antigen PET/CTObjective: A one-stop-shop. Hell J Nucl Med. 2017; 20 Suppl: 156.
- Schmidkonz C, Goetz TI, Kuwert T, et al. PSMA SPECT/CT with Tc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels. Ann Nucl Med. 2019; 33(12): 891–898.
- Yilmaz U, Komek H, Can C, et al. The role of (Ga)PSMA I&T in biochemical recurrence after radical prostatectomy: detection rate and the correlation between the level of PSA, Gleason score, and the SUV. Ann Nucl Med. 2019; 33(8): 545–553.
- Sheikhbahaei S, Jones KM, Werner RA, et al. F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies. Ann Nucl Med. 2019; 33(5): 351–361.
- Chau A, Gardiner P, Colletti PM, et al. Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases. Clin Nucl Med. 2018; 43(7): e226–e231.
- Teoh EJ, McGowan DR, Schuster DM, et al. Bayesian penalised likelihood reconstruction (Q.Clear) of F-fluciclovine PET for imaging of recurrent prostate cancer: semi-quantitative and clinical evaluation. Br J Radiol. 2018; 91(1085): 20170727.
- Oka S, Kanagawa M, Doi Y, et al. PET Tracer F-Fluciclovine Can Detect Histologically Proven Bone Metastatic Lesions: A Preclinical Study in Rat Osteolytic and Osteoblastic Bone Metastasis Models. Theranostics. 2017; 7(7): 2048–2064.
- Saudi A, Takhar P, Aljabery F, et al. Tc-MIP-1404 CZT SPECT/CT versus Ga/PSMA-11 PET/CT: Imaging of prostate cancer metastasis. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2023; 42(6): 413–415.
- Israel O, Pellet O, Biassoni L, et al. Two decades of SPECT/CT - the coming of age of a technology: An updated review of literature evidence. Eur J Nucl Med Mol Imaging. 2019; 46(10): 1990–2012.
- Filippi L, Urso L, Schillaci O, et al. [F]-FDHT PET for the Imaging of Androgen Receptor in Prostate and Breast Cancer: A Systematic Review. Diagnostics (Basel). 2023; 13(15).
- Ono M, Baden A, Okudaira H, et al. Assessment of Amino Acid/Drug Transporters for Renal Transport of [F]Fluciclovine (anti-[F]FACBC) in Vitro. Int J Mol Sci. 2016; 17(10).
- Jani AB, Schreibmann E, Rossi PJ, et al. Impact of F-Fluciclovine PET on Target Volume Definition for Postprostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial. J Nucl Med. 2017; 58(3): 412–418.
- Jadvar H. Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging. 2013; 40 Suppl 1(0 1): S5–10.
- Mei R, Farolfi A, Castellucci P, et al. PET/CT Variants and Pitfalls in Prostate Cancer: What You Might See on PET and Should Never Forget. Semin Nucl Med. 2021; 51(6): 621–632.
- Leyendecker P, Imperiale A, Matern JF, et al. Intense 18F-choline uptake after minor head injury: misleading PET/CT result in a patient with biochemical relapse of prostate adenocarcinoma. Clin Nucl Med. 2014; 39(11): 1012–1013.
- Liu J, Chen Z, Wang T, et al. Influence of Four Radiotracers in PET/CT on Diagnostic Accuracy for Prostate Cancer: A Bivariate Random-Effects Meta-Analysis. Cell Physiol Biochem. 2016; 39(2): 467–480.
- Schiavina R, Ceci F, Borghesi M, et al. The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques? Curr Radiopharm. 2013; 6(2): 92–95.
- Peeters C, Ponette D, van Poppel H. Salvage Pelvic Lymph Node Dissection after Radical Prostatectomy for Biochemical and Lymph Node Recurrence. Urol Int. 2017; 98(3): 367–369.
- Woo S, Ghafoor S, Vargas HA. Contribution of Radiology to Staging of Prostate Cancer. Semin Nucl Med. 2019; 49(4): 294–301.
- Vorster M, Modiselle M, Ebenhan T, et al. Fluorine-18-fluoroethylcholine PET/CT in the detection of prostate cancer: a South African experience. Hell J Nucl Med. 2015; 18(1): 53–59.
- Aydin AM, Haberal B, Artykov M, et al. Clinicopathological predictors of positive Ga-PSMA-11 PET/CT in PSA-only recurrence of localized prostate cancer following definitive therapy. Ann Nucl Med. 2019; 33(5): 326–332.
- Brito AET, Mourato FA, de Oliveira RPM, et al. Evaluation of whole-body tumor burden with Ga-PSMA PET/CT in the biochemical recurrence of prostate cancer. Ann Nucl Med. 2019; 33(5): 344–350.
- Couñago F, Díaz Gavela AA, Sancho G, et al. Multiparametric magnetic resonance imaging-guided salvage radiotherapy in prostate cancer. Rep Pract Oncol Radiother. 2019; 24(5): 472–480.
- Guo J, Liang L, Zhou N, et al. Quantitative Analysis of Ultrasound Tissue Diffusion Elastography in The Diagnosis of Benign and Malignant Prostate Lesions. Urol J. 2019; 16(4): 347–351.
- Hosseini SY, Alemi M, Amini E, et al. Prostate Specific Antigen Nadir After Radical Cystoprostatectomy in Patients With Benign Prostatic Tissue: A Benchmark To Define Biochemical Recurrence after Radical Prostatectomy. Urol J. 2019; 16(6): 563–566.
- Pietrzak A, Czepczynski R, Wierzchoslawska E, et al. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by F-FDG PET/CT. The role of Tc-MDP. Hell J Nucl Med. 2017; 20(3): 237–240.
- Pietrzak AK, Czepczynski R, Wierzchoslawska E, et al. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy? Urol J. 2018; 15(5): 242–247.
- Kratzik C, Dorudi S, Schatzl M, et al. Tc-99m-PSMA imaging allows successful radioguided surgery in recurrent prostate cancer. Hell J Nucl Med. 2018; 21(3): 202–204.
- Zaorsky NG, Yamoah K, Thakur ML, et al. A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer. Future Oncol. 2014; 10(3): 457–474.
- Wibmer AG, Burger IA, Sala E, et al. Molecular Imaging of Prostate Cancer. Radiographics. 2016; 36(1): 142–159.
- Pomykala KL, Czernin J, Grogan TR, et al. Total-Body Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines. J Nucl Med. 2020; 61(3): 405–411.
- Chen R, Wang Y, Shi Y, et al. Diagnostic value of F-FDG PET/CT in patients with biochemical recurrent prostate cancer and negative Ga-PSMA PET/CT. Eur J Nucl Med Mol Imaging. 2021; 48(9): 2970–2977.
- Schuster DM, Nanni C, Fanti S, et al. Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. J Nucl Med. 2014; 55(12): 1986–1992.
- Giesel FL, Knorr K, Spohn F, et al. Detection Efficacy of F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. J Nucl Med. 2019; 60(3): 362–368.
- Treglia G, Annunziata S, Pizzuto DA, et al. Detection Rate of F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis. Cancers (Basel). 2019; 11(5).
- Harmon SA, Mena E, Shih JH, et al. A comparison of prostate cancer bone metastases on F-Sodium Fluoride and Prostate Specific Membrane Antigen (F-PSMA) PET/CT: Discordant uptake in the same lesion. Oncotarget. 2018; 9(102): 37676–37688.
- Hohberg M, Kobe C, Krapf P, et al. Biodistribution and radiation dosimetry of [F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer. EJNMMI Res. 2019; 9(1): 66.
- Kuo HT, Lepage ML, Lin KS, et al. One-Step F-Labeling and Preclinical Evaluation of Prostate-Specific Membrane Antigen Trifluoroborate Probes for Cancer Imaging. J Nucl Med. 2019; 60(8): 1160–1166.
- Husarik DB, Miralbell R, Dubs M, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2008; 35(2): 253–263.
- Paymani Z, Rohringer T, Vali R, et al. [18F]fluorocholine PET/CT in the assessment of bone metastases in prostate cancer. Eur J Nucl Med Mol Imaging. 2007; 34(8): 1316–7; author reply 1318.
- Igerc I, Kohlfürst S, Gallowitsch HJ, et al. The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. Eur J Nucl Med Mol Imaging. 2008; 35(5): 976–983.